Pentraxin 3 in patients with severe sepsis or shock: the ALBIOS trial

Pietro Caironi; Serge Masson; Tommaso Mauri; Barbara Bottazzi; Roberto Leone; Michela Magnoli; Simona Barlera; Filippo Mamprin; Andrea Fedele; Alberto Mantovani; Gianni Tognoni; Antonio Pesenti; Luciano Gattinoni; Roberto Latini

doi:10.1111/eci.12704

Abstract

1 min read

In severe sepsis and septic shock, early high PTX3 predict subsequent new organ failures, while a smaller drop in circulating PTX3 over time predicts an increased risk of death. Patients with septic shock show lower levels of PTX3 when assigned to albumin than to crystalloids.

Related publications

Letter2021

Circulating pentraxin 3 in severe COVID‐19 or other pulmonary sepsis

Alessandro Protti, Jennifer Meessen, Barbara Bottazzi, Cecília Garlanda, Angelo Milani, Monica Bacci, Alberto Mantovani, Maurizio Cecconi, Roberto Latini, Pietro Caironi

Article2009

Severe sepsis in cirrhosis†

Thierry Gustot, François Durand, Didier Lebrec, Jean Louis Vincent, Richard Moreau

Article2011

Type of fluid in severe sepsis and septic shock.

Jean Louis Vincent, Leonardo Gottin

Article2004

Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock

R. Phillip Dellinger, Jean Carlet, Henry Masur, Herwig Gerlach, Thierry Calandra, Jonathan Cohen, Juan Gea‐Banacloche, Didier Keh, John C. Marshall, Margaret M. Parker, Graham Ramsay, Janice L. Zimmerman, Jean Louis Vincent, Mitchell M. Levy

Article2014

Cortisol Is an Associated-Risk Factor of Brain Dysfunction in Patients with Severe Sepsis and Septic Shock

Duc Nam Nguyen, Luc Huyghens, Haibo Zhang, Johan Schiettecatte, Johan Smitz, Jean Louis Vincent